Swiss drugmaker Roche said today that it had started late-stage trials for its experimental drug lampalizumab as a treatment for a serious eye disease.
The Basel-based firm has initiated Phase III trials for lampalizumab as a treatment for geographic atrophy, a leading cause of blindness in adults over 55, which gradually causes vision loss in the macula, making it harder to read, drive and recognise people’s faces.
